Investment Column: Chemring defensive in dangerous times

Alkane Energy; Alliance Pharma


Our view: Buy

Share price: 2160p (+170p)

We don't always get it right, but those of you who followed our advice towards the end of last year, when we first suggested buying Chemring shares at 1613p, can certainly afford a cheer.

The stars still seem aligned for the defence group, which makes consumable counter-measures and "energetics", such as flares. The public sector is its biggest client in a host of different countries, and it makes 60 per cent of its revenues in dollars and euros.

According to Chemring's brokers at Investec, turnover will reach £470m this year, up from £350m in 2008. The group's orders are up 39 per cent.

Yes, the stock has appreciated at a terrific rate in the past few months but, according to analysts at RBS, it is still worth buying. "The shares are currently trading on a October 2009 price earnings ratio of 10.1 times, and enterprise value to Ebitda of 6.7 times," they say. "This is still a significant discount to [a] number of larger, but in our view, lower quality peers in the FTSE 350 aerospace and defence sector[s]."

The shares are about as defensive as you get in these markets and, while we would not advise sitting on the stock indefinitely, if investors think the downturn will last for the foreseeable future, Chemring shares are worth keeping hold of.

Barring anything unexpected, and there was no sign of anything untoward yesterday's trading update, the shares will have a bumper 2009. Buy.

Alkane Energy

Our view: Buy

Share price: 16.5p (+1.75p)

You have to take your hat off to Alkane Energy. For good reason, and despite the misery for some companies in the continuing recession, it is upbeat about the future and says it is having no trouble in attracting investors, at least to meetings.

The Aim-listed company specialises in building and operating methane extraction plants, largely at disused mines in the Midlands. Alkane says the energy is clean and, with stellar full-year numbers announced yesterday, no debts and the price of its energy fixed for another year, the group is confident that its investors will benefit from holding the stock.

Neil O'Brien, Alkane's new chief executive, says he is excited about the future and that for the first time since the collapse of Lehman Brothers, he has filled up his diary for the next few days with meetings in the City – a sure sign that confidence is returning, albeit gradually. Whether this is the case is in our view questionable, but that does not detract from the fact that investors are prepared to listen to solid small caps with a good story. Alkane will start more projects this year, and the resultant power will not be locked in at current market levels, allowing the group to take advantage of higher energy prices in the coming year, Mr O'Brien says. A new site costs an average of £2.5m, and Alkane says it has enough cash in the bank to cover at least three projects this year.

There are clearly compelling reasons to buy Alkane shares. The big white elephant in the room, lest investors forget it, is that as a small-cap company, Alkane will suffer disproportionately with any slight change in sentiment. The shares rose 11.7 per cent yesterday and experts at house broker Brewin Dolphin predictably say the stock is a buy with a 24p price target. We would tentatively agree that they will rise. Buy.

Alliance Pharma

Our view: Hold

Share price: 8.25p (+1.1p)

To a casual observer, Alliance Pharma may not look too different to how it did two years ago. The chief executive, John Dawson, would disagree, saying that the group's marketing strategy has changed and, with a new venture capital investor, MVM, on board, the need for cash from outside to fund all-important acquisitions, has gone. The difference, Mr Dawson would argue, is reflected in its share price – up 75 per cent since December.

The group specialises in buying established, off-patent drugs that do not make enough money to attract generics firms. Yesterday, it published its full-year results, saying its pre-tax profits were £2.4m – up from a loss of £3.2m last year. Most significantly for investors, the group said it expects to start paying a dividend within the next 12 months. Despite the shares trading 15.8 per cent higher, analysts at house broker Numis reckon the stock is still undervalued. They said the shares were worth 11p, based on an average of sector peers' enterprise value to Ebitda.

While acknowledging that the shares have performed well in recent months, we see few catalysts from here. We would wait for some softening in the share price before buying. Hold.

Suggested Topics
PROMOTED VIDEO
News
ebooksAn unforgettable anthology of contemporary reportage
Voices
Oscar Pistorius is led out of court in Pretoria. Pistorius received a five-year prison sentence for culpable homicide by judge Thokozile Masipais for the killing of his girlfriend Reeva Steenkamp
voicesThokozile Masipa simply had no choice but to jail the athlete
Arts and Entertainment
Sister Cristina Scuccia sings 'Like a Virgin' in Venice
music

Like Madonna, Sister Cristina Scuccia's video is also set in Venice

Arts and Entertainment
James Blunt's debut album Back to Bedlam shot him to fame in 2004
music

Singer says the track was 'force-fed down people's throats'

News
i100
Life and Style
The Tinder app has around 10 million users worldwide

techThe original free dating app will remain the same, developers say

Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Helpdesk Analyst

£23000 per annum + pension and 22 days holiday: Ashdown Group: An established ...

Senior Helpdesk Analyst / Service Desk Co-ordinator

£27000 per annum + pension, 22 days holiday: Ashdown Group: An established ind...

Senior Pensions Administrator

£23000 - £26000 Per Annum: Clearwater People Solutions Ltd: Our client is curr...

Corporate Actions Administrator / Operations Administrator

£25 - 30k: Guru Careers: A Corporate Actions Administrator / Operations Admini...

Day In a Page

Two super-sized ships have cruised into British waters, but how big can these behemoths get?

Super-sized ships: How big can they get?

Two of the largest vessels in the world cruised into UK waters last week
British doctors on brink of 'cure' for paralysis with spinal cord treatment

British doctors on brink of cure for paralysis

Sufferers can now be offered the possibility of cure thanks to a revolutionary implant of regenerative cells
Let's talk about loss

We need to talk about loss

Secrecy and silence surround stillbirth
Will there be an all-female mission to Mars?

Will there be an all-female mission to Mars?

Women may be better suited to space travel than men are
Oscar Pistorius sentencing: The athlete's wealth and notoriety have provoked a long overdue debate on South African prisons

'They poured water on, then electrified me...'

If Oscar Pistorius is sent to jail, his experience will not be that of other inmates
James Wharton: The former Guard now fighting discrimination against gay soldiers

The former Guard now fighting discrimination against gay soldiers

Life after the Army has brought new battles for the LGBT activist James Wharton
Ebola in the US: Panic over the virus threatens to infect President Obama's midterms

Panic over Ebola threatens to infect the midterms

Just one person has died, yet November's elections may be affected by what Republicans call 'Obama's Katrina', says Rupert Cornwell
Premier League coaches join the RSC to swap the tricks of their trades

Darling, you were fabulous! But offside...

Premier League coaches are joining the RSC to learn acting skills, and in turn they will teach its actors to play football. Nick Clark finds out why
How to dress with authority: Kirsty Wark and Camila Batmanghelidjh discuss the changing role of fashion in women's workwear

How to dress with authority

Kirsty Wark and Camila Batmanghelidjh discuss the changing role of fashion in women's workwear
New book on Joy Division's Ian Curtis sheds new light on the life of the late singer

New book on Ian Curtis sheds fresh light on the life of the late singer

'Joy Division were making art... Ian was for real' says author Jon Savage
Sean Harris: A rare interview with British acting's secret weapon

Sean Harris: A rare interview with British acting's secret weapon

The Bafta-winner talks Hollywood, being branded a psycho, and how Barbra Streisand is his true inspiration
Tim Minchin, interview: The musician, comedian and world's favourite ginger is on scorching form

Tim Minchin interview

For a no-holds-barred comedian who is scathing about woolly thinking and oppressive religiosity, he is surprisingly gentle in person
Boris Johnson's boozing won't win the puritan vote

Boris's boozing won't win the puritan vote

Many of us Brits still disapprove of conspicuous consumption – it's the way we were raised, says DJ Taylor
Ash frontman Tim Wheeler reveals how he came to terms with his father's dementia

Tim Wheeler: Alzheimer's, memories and my dad

Wheeler's dad suffered from Alzheimer's for three years. When he died, there was only one way the Ash frontman knew how to respond: with a heartfelt solo album